Get Connected:

The MD Magazine Neurology specialty page provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

Latest Headlines

Those Deep Gray and White Matter Images Are Important in Multiple Sclerosis
MR-PET imaging can reveal inflammation and neurodegeneration in the brain, among other things, and a recent study showed that it can also help determine the progression of multiple sclerosis (MS).
With some patients being treated for multiple sclerosis with Aubagio for more than a decade questions have been raised about the safety of the treatment for such a long period of time. Further research has shown it to still be safe for the people who need it most.
It can be easy to look at the treatment of multiple sclerosis and stop at the physical symptoms of the disease. For patients living with the condition their daily lives are about more than the symptoms and making them work within their own individual challenges.
Magnetic resonance imaging (MRI) can be used to identify lesions in the central nervous system in patients with multiple sclerosis (MS), but not all patients with active disease have identifiable lesions, and researchers are mixed over the extent to which lesions can be used as a marker for MS disease activity.
Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF) is effective at lowering disease activity long-term in patients with relapsing-remitting multiple sclerosis (RRMS), according to Eva Havrdova, MD, of Charles University of Prague. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.
When it comes to treating and studying multiple sclerosis, the correlation between magnetic resonance imaging (MRI) lesions and actual disease activity has been widely disputed. A new analysis says that using MRI lesions as a proxy for disease activity is a sufficient approach when determining primary endpoints in clinical trials.
The results from an on-going phase 4 trial add to the growing evidence that teriflunomide is effective for relapsing-remitting multiple sclerosis, according to Patricia K. Coyle, MD, of Stony Brook University in New York.

Most Popular in Neurology

Recent Published Journal

$vacMongoViewPlus$ $vAR$